FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1602659283> ?p ?o ?g. }

• W1602659283 endingPage "528" @default.
• W1602659283 startingPage "524" @default.
• W1602659283 abstract "The use of soluble cardiac biomarkers such as N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin‐3 have also been reported to have prognostic value in other cardiac patient populations. We identified 502 patients with AL amyloidosis, who provided a research sample and consent to review their medical records between 1/1/2006‐12/31/2010 within 90 days of their diagnosis. Samples were assayed for sST2 and galectin‐3. Within this AL amyloidosis population, overall survival (OS) was 25.5 months (95% CI 18, 35.7 months). Receiver operating curve analyses were done to detect the best cut‐points for sST2 and galectin‐3 to predict both 1‐ and 5‐year OS. The respective cut points for sST2 were 30 and 29.7 ng/mL, while the median sST2 for the entire population was 31 ng/mL (IQR 19.8, 53.6). The respective cut points for galectin‐3 were 11 and 10.4 ng/mL while the median for the entire population was 16.6 ng/mL (IQR 11.5, 24.0). Although on univariate analysis, both sST2 and galectin‐3 were prognostic, upon multivariate analysis, only sST2 was independent of troponin, NT‐proBNP, serum immunoglobulin free light chain, and blood pressure. Not only did sST2 add to previously reported prognostication systems, but a novel prognostication 5‐point system including sST2 was possible. The addition of sST2 – but not galectin‐3 – to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death. Am. J. Hematol. 90:524–528, 2015. © 2015 Wiley Periodicals, Inc." @default.
• W1602659283 created "2016-06-24" @default.
• W1602659283 creator A5000308170 @default.
• W1602659283 creator A5001453763 @default.
• W1602659283 creator A5007747233 @default.
• W1602659283 creator A5011577694 @default.
• W1602659283 creator A5012403700 @default.
• W1602659283 creator A5012884078 @default.
• W1602659283 creator A5012985685 @default.
• W1602659283 creator A5016853434 @default.
• W1602659283 creator A5023193953 @default.
• W1602659283 creator A5026574827 @default.
• W1602659283 creator A5029802364 @default.
• W1602659283 creator A5033220547 @default.
• W1602659283 creator A5052346975 @default.
• W1602659283 creator A5066940168 @default.
• W1602659283 creator A5072877047 @default.
• W1602659283 creator A5075187080 @default.
• W1602659283 creator A5076131604 @default.
• W1602659283 creator A5076611748 @default.
• W1602659283 date "2015-04-02" @default.
• W1602659283 modified "2023-09-26" @default.
• W1602659283 title "Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T" @default.
• W1602659283 cites W1629710342 @default.
• W1602659283 cites W1969551915 @default.
• W1602659283 cites W1973853538 @default.
• W1602659283 cites W1976096054 @default.
• W1602659283 cites W1994877692 @default.
• W1602659283 cites W1998421355 @default.
• W1602659283 cites W2009737338 @default.
• W1602659283 cites W2011953819 @default.
• W1602659283 cites W2014464830 @default.
• W1602659283 cites W2021008306 @default.
• W1602659283 cites W2021460241 @default.
• W1602659283 cites W2039485943 @default.
• W1602659283 cites W2039669614 @default.
• W1602659283 cites W2047565570 @default.
• W1602659283 cites W2047784590 @default.
• W1602659283 cites W2048813343 @default.
• W1602659283 cites W2050211927 @default.
• W1602659283 cites W2051051386 @default.
• W1602659283 cites W2054721388 @default.
• W1602659283 cites W2062215577 @default.
• W1602659283 cites W2066268381 @default.
• W1602659283 cites W2068898313 @default.
• W1602659283 cites W2076386837 @default.
• W1602659283 cites W2080338438 @default.
• W1602659283 cites W2085853487 @default.
• W1602659283 cites W2098093182 @default.
• W1602659283 cites W2100267854 @default.
• W1602659283 cites W2104174124 @default.
• W1602659283 cites W2107403553 @default.
• W1602659283 cites W2107985278 @default.
• W1602659283 cites W2116707579 @default.
• W1602659283 cites W2122622124 @default.
• W1602659283 cites W2144506100 @default.
• W1602659283 cites W2158872147 @default.
• W1602659283 cites W2159352020 @default.
• W1602659283 cites W2168130167 @default.
• W1602659283 cites W2168613652 @default.
• W1602659283 cites W2171033052 @default.
• W1602659283 doi "https://doi.org/10.1002/ajh.24001" @default.
• W1602659283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25753178" @default.
• W1602659283 hasPublicationYear "2015" @default.
• W1602659283 type Work @default.
• W1602659283 sameAs 1602659283 @default.
• W1602659283 citedByCount "29" @default.
• W1602659283 countsByYear W16026592832015 @default.
• W1602659283 countsByYear W16026592832016 @default.
• W1602659283 countsByYear W16026592832017 @default.
• W1602659283 countsByYear W16026592832018 @default.
• W1602659283 countsByYear W16026592832019 @default.
• W1602659283 countsByYear W16026592832020 @default.
• W1602659283 countsByYear W16026592832021 @default.
• W1602659283 countsByYear W16026592832022 @default.
• W1602659283 countsByYear W16026592832023 @default.
• W1602659283 crossrefType "journal-article" @default.
• W1602659283 hasAuthorship W1602659283A5000308170 @default.
• W1602659283 hasAuthorship W1602659283A5001453763 @default.
• W1602659283 hasAuthorship W1602659283A5007747233 @default.
• W1602659283 hasAuthorship W1602659283A5011577694 @default.
• W1602659283 hasAuthorship W1602659283A5012403700 @default.
• W1602659283 hasAuthorship W1602659283A5012884078 @default.
• W1602659283 hasAuthorship W1602659283A5012985685 @default.
• W1602659283 hasAuthorship W1602659283A5016853434 @default.
• W1602659283 hasAuthorship W1602659283A5023193953 @default.
• W1602659283 hasAuthorship W1602659283A5026574827 @default.
• W1602659283 hasAuthorship W1602659283A5029802364 @default.
• W1602659283 hasAuthorship W1602659283A5033220547 @default.
• W1602659283 hasAuthorship W1602659283A5052346975 @default.
• W1602659283 hasAuthorship W1602659283A5066940168 @default.
• W1602659283 hasAuthorship W1602659283A5072877047 @default.
• W1602659283 hasAuthorship W1602659283A5075187080 @default.
• W1602659283 hasAuthorship W1602659283A5076131604 @default.
• W1602659283 hasAuthorship W1602659283A5076611748 @default.
• W1602659283 hasBestOaLocation W16026592831 @default.
• W1602659283 hasConcept C126322002 @default.
• W1602659283 hasConcept C142724271 @default.

• next